Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 911-358-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral toxicity:
The acute oral toxicity dose (LD50) for Reaction mass of 1,4-bis(butylamino)anthraquinone and 1,4-bis(methylamino)anthraquinone and 1,4-bis[(2-ethylhexyl)amino]anthraquinone and 1-(butylamino)-4-(methylamino)anthraquinone and 1-(butylamino)-4-[(2-ethylhexyl)amino]anthraquinone and 1-[(2-ethylhexyl)amino]-4-(methylamino)anthraquinone (EC No.: 911-358-0) was considered based on prediction studies and data available for the structurally and functionally similar read across chemicals. The LD50 value is >2000 mg/kg bw.Thus, comparing this value with the criteria of CLP regulation, Reaction mass of 1,4-bis(butylamino)anthraquinone and 1,4-bis(methylamino)anthraquinone and 1,4-bis[(2-ethylhexyl)amino]anthraquinone and 1-(butylamino)-4-(methylamino)anthraquinone and 1-(butylamino)-4-[(2-ethylhexyl)amino]anthraquinone and 1-[(2-ethylhexyl)amino]-4-(methylamino)anthraquinone cannot be classified for acute oral toxicity.
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Remarks:
- experimental data of read across substances
- Justification for type of information:
- Data for the target chemical is summarized based on the predicted data and structurally and functionally similar read across chemicals
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Qualifier:
- according to guideline
- Guideline:
- other: As mentioned below
- Principles of method if other than guideline:
- WoE report is based on 6 acute oral toxicity studies as - WoE-2 to WoE-7.
Acute Oral toxicity test was carried out to study the effects of the test chemicals on rodents. - GLP compliance:
- not specified
- Test type:
- other: not specified
- Limit test:
- no
- Specific details on test material used for the study:
- - Name of test material : Reaction mass of 1,4-bis(butylamino)anthraquinone and 1,4-bis(methylamino)anthraquinone and 1,4-bis[(2-ethylhexyl)amino]anthraquinone and 1-(butylamino)-4-(methylamino)anthraquinone and 1-(butylamino)-4-[(2-ethylhexyl)amino]anthraquinone and 1-[(2-ethylhexyl)amino]-4-(methylamino)anthraquinone
- Substance type : Organic
- Physical state : Solid - Species:
- rat
- Strain:
- other: WoE-2 to WoE-5 - not specified; WoE-6 - not specified; WoE-7 - Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- WoE-2 to WoE-5 - not specified;
WoE-6 - not specified;
WoE-7 - TEST ANIMALS
- Source: National Institute of Biosciences, Pune
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: approximately 8 to 12 weeks old
- Weight at study initiation: Body weight range was 199.8 to 211.7 grams.
Body weights at the start : Mean: 204.54 g (= 100 %), Minimum : 199.8 g (- 2.32 %), Maximum : 211.7 g (+ 3.50 %)
- Fasting period before study: approximately 16 hours or more
- Housing: The rats were housed in polycarbonate cages.
- Diet (e.g. ad libitum): Rodent feed supplied ad libitum.
- Water (e.g. ad libitum):Water was provided ad libitum from individual bottles attached to the cages.
- Acclimation period: at least 5 days prior to administration
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20.1 to 21.9 °C
- Humidity (%): 56.3% to 59.8%
- Air changes (per hr): at least 10 to 15 air changes/hour of 100% fresh air that had been passed through the HEPA filters.
- Photoperiod (hrs dark / hrs light): An artificial light and dark cycle of 12 hours each was provided to the room
IN-LIFE DATES: From: 08-06-2017 To:02-08-2017 - Route of administration:
- other: WoE-2 to WoE-5 - oral: unspecified; WoE-6 - oral: unspecified; WoE-7 - oral: gavage
- Vehicle:
- other: WoE-2 to WoE-5 - not specified; WoE-6 - not specified; WoE-7 - corn oil
- Details on oral exposure:
- WoE-2 to WoE-5 - not specified;
WoE-6 - not specified;
WoE-7 - VEHICLE
- Concentration in vehicle: 300 mg/kg and 2000 mg/kg
- Amount of vehicle (if gavage):10 ml/kg body weight
- Justification for choice of vehicle: Given test solution is soluble in corn oil.
MAXIMUM DOSE VOLUME APPLIED: 2000 mg/kg
DOSAGE PREPARATION (if unusual): The test item was prepared by dilution of the test item in corn oil to obtain 30 mg/ml strength of solution. The formulation was prepared fresh on the day of dosing. The test item was administered in the dose volume of 10 ml/kg body weight.
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: 300 mg/kg - Doses:
- WoE-2 - 5500 mg/kg bw
WoE-3 - 4600 mg/kg bw
WoE-4 - 3500 mg/kg bw
WoE-5 - 3100 mg/kg bw
WoE-6 - 4350 mg/kg bw
WoE-7 - 300 mg/kg and 2000 mg/kg - No. of animals per sex per dose:
- WoE-2 to WoE-5 - not specified;
WoE-6 - not specified;
WoE-7 - Total - 12 (Females); Step I (300 mg/kg) - 3; Step II (300 mg/kg) - 3; Step I (2000 mg/kg) - 3; Step II (2000 mg/kg) - 3 - Control animals:
- not specified
- Details on study design:
- WoE-2 to WoE-5 - not specified;
WoE-6 - not specified;
WoE-7 - Duration of observation period following administration: 14 days
- Frequency of observations :Animals were observed for clinical signs, mortality and morbidity, until sacrifice.The clinical signs and mortality observations were conducted at immediately (0 to 5 minutes), 5, 10, 30, 60 minutes, 2, 4 and 6 hours on the day of dosing and once daily thereafter for 14 day. Daily observation was done as far as possible at the same time.
- Weighing: Individual animal body weights were recorded, before fasting, prior to administration of the test item (fasting body weights), weekly thereafter and at termination on day 14. Weight changes were calculated and recorded.
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,organ weights, histopathology, were performed. - Statistics:
- WoE-2 to WoE-5 - not specified;
WoE-6 - not specified;
WoE-7 - not specified; - Preliminary study:
- WoE-2 to WoE-5 - not specified;
WoE-6 - not specified;
WoE-7 - not specified; - Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 5 500 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: 50% mortality was observed
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 4 600 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: 50% mortality was observed
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 3 500 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: 50% mortality was observed
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 3 100 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: 50% mortality was observed
- Sex:
- not specified
- Dose descriptor:
- LD50
- Effect level:
- 4 350 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: 50% mortality was observed
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: No mortality was observed
- Mortality:
- WoE-2 to WoE-5 - not specified;
WoE-6 - 50% mortality was observed
WoE-7 - No mortality was observed at 2000 mg/kg. - Clinical signs:
- other: WoE-2 to WoE-5 - not specified; WoE-6 - not specified; WoE-7 - Group I Step I and II : At 300 mg/kg There was no signs of toxicity on day 2 after the dosing; coloured faces and diarrhoea with onset from 4 hours to day 1 after the dosing was observed. G
- Gross pathology:
- WoE-2 to WoE-5 - not specified;
WoE-6 - not specified;
WoE-7 - Gross pathological examination did not reveal any abnormalities in animals from 300 mg/kg and 2000 mg/kg dose groups. - Other findings:
- WoE-2 to WoE-5 - not specified;
WoE-6 - not specified;
WoE-7 - No data - Interpretation of results:
- other: Not classified
- Conclusions:
- According to CLP regulation the test chemical Reaction mass of 1,4-bis(butylamino)anthraquinone and 1,4-bis(methylamino)anthraquinone and 1,4-bis[(2-ethylhexyl)amino]anthraquinone and 1-(butylamino)-4-(methylamino)anthraquinone and 1-(butylamino)-4-[(2-ethylhexyl)amino]anthraquinone and 1-[(2-ethylhexyl)amino]-4-(methylamino)anthraquinone (EC No.: 911-358-0) cannot be classified for acute oral toxicity, as the LD50 value is >2000 mg/kg bw.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- Data is Klimisch 2 and from database.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Acute oral toxicity:
In different studies, Reaction mass of 1,4-bis(butylamino)anthraquinone and 1,4-bis(methylamino)anthraquinone and 1,4-bis[(2-ethylhexyl)amino]anthraquinone and 1-(butylamino)-4-(methylamino)anthraquinone and 1-(butylamino)-4-[(2-ethylhexyl)amino]anthraquinone and 1-[(2-ethylhexyl)amino]-4-(methylamino)anthraquinone (EC No.: 911-358-0) has been investigated for acute oral toxicity to a greater or lesser extent. Often are the studies based on in-vivo experiments in rodents, i.e. most commonly in rats for Reaction mass of 1,4-bis(butylamino)anthraquinone and 1,4-bis(methylamino)anthraquinone and 1,4-bis[(2-ethylhexyl)amino]anthraquinone and 1-(butylamino)-4-(methylamino)anthraquinone and 1-(butylamino)-4-[(2-ethylhexyl)amino]anthraquinone and 1-[(2-ethylhexyl)amino]-4-(methylamino)anthraquinone along with the studies available on its structurally and functionally similar read across substances. The predicted data using the Danish QSAR has also been considered. The studies are summarized as below –
Based on the QSAR prediction done using the Danish (Q)SAR Database, the acute oral toxicity was estimated for Reaction mass of 1,4-bis(butylamino)anthraquinone and 1,4-bis(methylamino)anthraquinone and 1,4-bis[(2-ethylhexyl)amino]anthraquinone and 1-(butylamino)-4-(methylamino)anthraquinone and 1-(butylamino)-4-[(2-ethylhexyl)amino]anthraquinone and 1-[(2-ethylhexyl)amino]-4-(methylamino)anthraquinone (EC No.: 911-358-0). The LD50 values were estimated to be 5500, 4600, 3500, and 3100 mg/kg bw, with moderate prediction quality (0.5-0.75), when rats were treated via oral route.
The above prediction is supported with the data available for the structurally and functionally similar read across chemicals. The studies are summarized as below –
1. Acute oral toxicity study of test chemical was conducted in rat at the concentration of 4350 mg/kg bw. 50% mortality was observed at 5000 mg/kg bw. Therefore, LD50 was considered to be 4350 mg/kg bw, when rats were treated with test chemical via oral route.
2. In a acute oral toxicity study, 12 Sprague Dawley female rats treated with test chemical by oral gavage route at the concentration of 300 and 2000 mg/kg bw in 4 different steps. The dose of 300 mg/kg of test item was prepared by dilution of the test item in corn oil to obtain 30 mg/ml strength of solution. The formulation was prepared fresh on the day of dosing. The test item was administered in the dose volume of 10 ml/kg body weight. The dose of 2000 mg/kg of test item was administered undiluted. Female rats (taken from National Institute of Biosciences, Pune) of the age of approximately 8 to 12 weeks old were used and its weight were within ± 20% of the mean weight of any animal used for dosing. Body weight range was 199.8 to 211.7 grams. The rats were housed in polycarbonate cages.The animal room was independently provided with at least 10 to 15 air changes per hour of 100% fresh air that had been passed through the HEPA filters. Room temperature was maintained at 20.1 to 21.9° C and room humidity was maintained at 56.3% to 59.8%.An artificial light and dark cycle of 12 hours each was provided to the room. Rodent feed supplied by the Nutrivet Life Sciences, Pune, was provided ad libitum from individual feeders. Water was provided ad libitum from individual bottles attached to the cages. All water was from a local source and passed through the reverse osmosis membrane before use. The single dose of test item was administered to fasted rats (approximately 16 hours or more) by oral intubation, using a ball-tipped intubation needle fitted onto a syringe of appropriate size. Initially, 3 female animals were treated at the dose level of 300 mg/kg body weight of the test item (Step - I). Administration of the test item at 300 mg/kg resulted in test item coloured faces and diarrhoea with onset from 4 hours to day 1 after the dosing and no mortality at 24 hours after the dosing. As no mortality was observed at 24 hours after the dosing, 3 female animals were added to the study and treated with the same dose of 300 mg/kg of the test item (Step - II). Administration of the test item at 300 mg/kg resulted in test item coloured faces and diarrhoea with onset from 4 hours to day 1 after the dosing and no mortality after the dosing. No mortality was observed at 300 mg/kg dose group, hence additional 3 female animals were treated with the higher dose of 2000 mg/kg of the test item (Step - I). Administration of the test item at 2000 mg/kg resulted in test item coloured faces with onset on day 1 after the dosing and no mortality after the dosing. As no mortality were observed at 24 hours after the dosing, additional 3 female animals were treated with the higher dose of 2000 mg/kg of the test item (Step - II). Administration of the test item at 2000 mg/kg resulted in test item coloured faces with onset on day 1 after the dosing and no mortality after the dosing. Gross pathological examination did not reveal any abnormalities in animals from 300 mg/kg and 2000 mg/kg dose groups. Therefore, LD50 value of the test compound was considered to be >2000 mg/kg bw, when Sprague Dawley female rats treated via oral gavage route.
Thus, based on the above summarised studies, Reaction mass of 1,4-bis(butylamino)anthraquinone and 1,4-bis(methylamino)anthraquinone and 1,4-bis[(2-ethylhexyl)amino]anthraquinone and 1-(butylamino)-4-(methylamino)anthraquinone and 1-(butylamino)-4-[(2-ethylhexyl)amino]anthraquinone and 1-[(2-ethylhexyl)amino]-4-(methylamino)anthraquinone (EC No.: 911-358-0) and it’s structurally and functionally similar read across substances, it can be concluded that LD50 value is >2000 mg/kg bw. Thus, comparing this value with the criteria of CLP regulation, Reaction mass of 1,4-bis(butylamino)anthraquinone and 1,4-bis(methylamino)anthraquinone and 1,4-bis[(2-ethylhexyl)amino]anthraquinone and 1-(butylamino)-4-(methylamino)anthraquinone and 1-(butylamino)-4-[(2-ethylhexyl)amino]anthraquinone and 1-[(2-ethylhexyl)amino]-4-(methylamino)anthraquinone cannot be classified for acute oral toxicity.
Justification for classification or non-classification
Based on the above studies and prediction, Reaction mass of 1,4-bis(butylamino)anthraquinone and 1,4-bis(methylamino)anthraquinone and 1,4-bis[(2-ethylhexyl)amino]anthraquinone and 1-(butylamino)-4-(methylamino)anthraquinone and 1-(butylamino)-4-[(2-ethylhexyl)amino]anthraquinone and 1-[(2-ethylhexyl)amino]-4-(methylamino)anthraquinone (EC No.: 911-358-0) and it’s structurally and functionally similar read across substances, it can be concluded that LD50 value is >2000 mg/kg bw, for acute oral toxicity. Thus, comparing this value with the criteria of CLP regulation, Reaction mass of 1,4-bis(butylamino)anthraquinone and 1,4-bis(methylamino)anthraquinone and 1,4-bis[(2-ethylhexyl)amino]anthraquinone and 1-(butylamino)-4-(methylamino)anthraquinone and 1-(butylamino)-4-[(2-ethylhexyl)amino]anthraquinone and 1-[(2-ethylhexyl)amino]-4-(methylamino)anthraquinone cannot be classified for acute oral toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.